Skip to content

Kynam Capital Management, LP

Follow

13F filer, CIK 1907884, PRINCETON, NJ

Kynam Capital Management, LP reported $1,806,156,492 across 34 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 72.29% of the portfolio.

Accepted , ingested 13F-HR 0001907884-26-000017

Period
2026-09-30
Reported value
$1.81B
Holdings
34
Top 10 weight
72.29%
New
4
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
LEGNadded+6,153,184$122M
SMMTadded+1,800,000$30.4M
BEAMadded+1,093,102$26.7M
SRZNnew+486,252$15.6M
XENEnew+280,000$10.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PCVXreduced-314,371-$17.9M
INSMexited-100,000-$10.7M
RLAYreduced-548,500-$9.9M
CLDXreduced-256,857-$8.32M
VRDNreduced-305,877-$6.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001907884-26-000017, largest first. % of portfolio is the value over $1,806,156,492, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
LEGNLEGEND BIOTECH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 610,000 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,576,295 shares; 2026Q2: 3,001,205 shares; 2026Q3: 9,154,389 shares 9,154,389$182M10.08%+6,153,184Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 5,064,207 shares; 2025Q1: 6,500,000 shares; 2025Q2: 6,100,729 shares; 2025Q3: 6,100,729 shares; 2025Q4: 5,943,180 shares; 2026Q1: 5,840,567 shares; 2026Q2: 5,322,908 shares; 2026Q3: 5,066,051 shares 5,066,051$164M9.09%-256,857Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 8,520,000 shares; 2025Q1: 8,520,000 shares; 2025Q2: 8,520,000 shares; 2025Q3: 8,520,000 shares; 2025Q4: 8,050,959 shares; 2026Q1: 8,050,959 shares; 2026Q2: 8,050,959 shares; 2026Q3: 8,150,959 shares 8,150,959$153M8.48%+100,000Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,336,796 shares; 2025Q1: 3,200,000 shares; 2025Q2: 3,071,588 shares; 2025Q3: 3,071,588 shares; 2025Q4: 2,922,335 shares; 2026Q1: 2,922,335 shares; 2026Q2: 2,922,335 shares; 2026Q3: 2,607,964 shares 2,607,964$148M8.22%-314,371Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,326,262 shares; 2025Q1: 4,700,000 shares; 2025Q2: 4,427,927 shares; 2025Q3: 4,427,927 shares; 2025Q4: 1,470,541 shares; 2026Q1: 2,341,652 shares; 2026Q2: 6,453,877 shares; 2026Q3: 6,148,000 shares 6,148,000$127M7.01%-305,877Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 9,105,000 shares; 2025Q1: 9,105,000 shares; 2025Q2: 8,492,557 shares; 2025Q3: 7,886,172 shares; 2025Q4: 6,165,223 shares; 2026Q1: 4,037,331 shares; 2026Q2: 3,667,097 shares; 2026Q3: 3,792,289 shares 3,792,289$121M6.72%+125,192Timeline
TVTXTRAVERE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,802,750 shares; 2025Q1: 1,802,750 shares; 2025Q2: 1,540,691 shares; 2025Q3: 949,727 shares; 2025Q4: 517,884 shares; 2026Q1: 1,569,018 shares; 2026Q2: 2,000,000 shares; 2026Q3: 2,000,000 shares 2,000,000$118M6.52%0Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 25,000 shares; 2025Q2: 656,573 shares; 2025Q3: 282,412 shares; 2025Q4: not reported; 2026Q1: 2,247,393 shares; 2026Q2: 2,434,207 shares; 2026Q3: 2,434,207 shares 2,434,207$98.9M5.48%0Timeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,457,910 shares; 2025Q1: 2,400,000 shares; 2025Q2: 3,426,887 shares; 2025Q3: 4,027,800 shares; 2025Q4: 3,433,051 shares; 2026Q1: 3,398,224 shares; 2026Q2: 2,890,059 shares; 2026Q3: 3,000,000 shares 3,000,000$96.9M5.36%+109,941Timeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,756,158 shares; 2025Q1: 2,518,170 shares; 2025Q2: 2,417,647 shares; 2025Q3: 2,517,647 shares; 2025Q4: 2,440,214 shares; 2026Q1: 3,682,185 shares; 2026Q2: 2,840,792 shares; 2026Q3: 3,933,894 shares 3,933,894$96.2M5.33%+1,093,102Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 2,154,413 shares; 2025Q3: 3,646,503 shares; 2025Q4: 8,966,077 shares; 2026Q1: 15,013,093 shares; 2026Q2: 21,703,093 shares; 2026Q3: 21,140,726 shares 21,140,726$57.5M3.18%-562,367Timeline
MBXMBX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,000,000 shares; 2025Q4: 934,799 shares; 2026Q1: 934,799 shares; 2026Q2: 934,799 shares; 2026Q3: 934,799 shares 934,799$54.8M3.03%0Timeline
SMMTSUMMIT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,200,000 shares; 2026Q3: 3,000,000 shares 3,000,000$50.7M2.81%+1,800,000Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,000,000 shares; 2025Q1: 3,063,292 shares; 2025Q2: 2,887,014 shares; 2025Q3: 2,887,014 shares; 2025Q4: 1,424,259 shares; 2026Q1: 1,424,259 shares; 2026Q2: 3,300,000 shares; 2026Q3: 2,751,500 shares 2,751,500$49.7M2.75%-548,500Timeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,252,738 shares; 2025Q1: 2,338,629 shares; 2025Q2: 2,095,998 shares; 2025Q3: 2,302,172 shares; 2025Q4: 3,114,132 shares; 2026Q1: 3,114,132 shares; 2026Q2: 3,114,132 shares; 2026Q3: 3,114,132 shares 3,114,132$47.8M2.65%0Timeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,225,576 shares; 2025Q1: 1,695,576 shares; 2025Q2: 976,267 shares; 2025Q3: 1,009,267 shares; 2025Q4: 856,462 shares; 2026Q1: 884,937 shares; 2026Q2: 1,375,000 shares; 2026Q3: 1,375,000 shares 1,375,000$41.6M2.31%0Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 800,000 shares; 2025Q2: 1,173,605 shares; 2025Q3: 2,168,605 shares; 2025Q4: 1,970,357 shares; 2026Q1: 1,194,757 shares; 2026Q2: 1,194,757 shares; 2026Q3: 1,194,757 shares 1,194,757$28.3M1.57%0Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 675,000 shares; 2025Q4: 640,395 shares; 2026Q1: 640,395 shares; 2026Q2: 661,795 shares; 2026Q3: 824,843 shares 824,843$26.2M1.45%+163,048Timeline
BNRBURNING ROCK BIOTECH LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 994,883 shares; 2025Q1: 994,883 shares; 2025Q2: 994,883 shares; 2025Q3: 994,883 shares; 2025Q4: 994,883 shares; 2026Q1: 1,227,555 shares; 2026Q2: 1,238,563 shares; 2026Q3: 1,238,563 shares 1,238,563$21.8M1.21%0Timeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 9,085,368 shares; 2025Q1: 8,928,523 shares; 2025Q2: 8,463,742 shares; 2025Q3: 9,390,270 shares; 2025Q4: 9,366,526 shares; 2026Q1: 5,680,795 shares; 2026Q2: 2,522,660 shares; 2026Q3: 2,522,660 shares 2,522,660$21M1.16%0Timeline
SRZNSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 486,252 shares 486,252$15.6M0.87%newTimeline
STROSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 479,590 shares; 2026Q1: 872,558 shares; 2026Q2: 872,558 shares; 2026Q3: 872,558 shares 872,558$14.1M0.78%0Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 280,000 shares 280,000$10.4M0.58%newTimeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 185,482 shares; 2026Q1: 625,496 shares; 2026Q2: not reported; 2026Q3: 1,200,000 shares 1,200,000$9.91M0.55%newTimeline
PRLDPRELUDE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 788,867 shares; 2026Q1: 1,592,551 shares; 2026Q2: 2,415,087 shares; 2026Q3: 2,311,955 shares 2,311,955$9.04M0.5%-103,132Timeline
GERNGERON CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 3,659,526 shares; 2025Q2: 3,456,318 shares; 2025Q3: 3,456,318 shares; 2025Q4: 3,456,318 shares; 2026Q1: 6,836,318 shares; 2026Q2: 6,836,318 shares; 2026Q3: 6,836,318 shares 6,836,318$8.41M0.47%0Timeline
PBLSPARABILIS MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 250,000 shares; 2026Q3: 250,000 shares 250,000$8.07M0.45%0Timeline
ALECALECTOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,000,000 shares; 2026Q1: 2,000,000 shares; 2026Q2: 3,808,494 shares; 2026Q3: 4,308,494 shares 4,308,494$7.97M0.44%+500,000Timeline
AMRNAMARIN CORP PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 576,111 shares; 2025Q3: 576,111 shares; 2025Q4: 389,273 shares; 2026Q1: 472,382 shares; 2026Q2: 532,982 shares; 2026Q3: 532,982 shares 532,982$6.93M0.38%0Timeline
HROWHARROW INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 124,655 shares 124,655$3.84M0.21%newTimeline
CRBUCARIBOU BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,406,147 shares; 2025Q1: 3,269,147 shares; 2025Q2: 3,067,774 shares; 2025Q3: 3,067,774 shares; 2025Q4: 2,503,302 shares; 2026Q1: 2,503,302 shares; 2026Q2: 2,503,302 shares; 2026Q3: 2,503,302 shares 2,503,302$3.18M0.18%0Timeline
PRQRPROQR THRAPEUTICS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,750,000 shares; 2025Q1: 1,750,000 shares; 2025Q2: 1,649,462 shares; 2025Q3: 1,649,462 shares; 2025Q4: 1,566,317 shares; 2026Q1: 1,566,317 shares; 2026Q2: 1,566,317 shares; 2026Q3: 1,566,317 shares 1,566,317$2.6M0.14%0Timeline
ENGNENGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 457,855 shares; 2026Q3: 457,855 shares 457,855$916K0.05%0Timeline
TRAWTRAWS PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 84,400 shares; 2026Q3: 84,400 shares 84,400$50.1K<0.01%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
INSMINSMED INC100,000$10.7Mshares
CADLCANDEL THERAPEUTICS INC96,741$996Kshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001907884-26-000017 base2026-11-16